Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer
{{output}}
In the setting of differentiated thyroid cancer (DTC) management, < 0.1 mU/L TSH suppression has been proven to be beneficial for patients likely to have microscopic or macroscopic disease, as TSH has a direct trophic effect on thyroid cancer cells. However, t... ...
